Doxorubicin
别名: Adriamycin,Hydroxydaunorubicin,DOX
中文名称:阿霉素,多柔比星
目录号:E2516 Purity: 99.71%
Adriamycin (Doxorubicin, Hydroxydaunorubicin)是一种细胞毒性蒽环类抗生素,也是一种抗癌化疗药物,以IC50为2.67 μM抑制拓扑异构酶II(topoisomerase II,topo II),从而阻止DNA复制,诱导细胞凋亡,同时抑制人DNA拓扑异构酶I(Topoisomerase I,topo I),IC50为0.8 μM。
CAS: 23214-92-8
客户使用Selleck的Doxorubicin发表文献122篇
- Adv Sci (Weinh), 2025 12(1):e2404109
- Nat Commun, 2024 15(1):4450
- Nat Commun, 2024 15(1):1041
- Theranostics, 2024 14(9):3719-3738
- Redox Biol, 2024 79:103479
- Redox Biol, 2024 70:103067
- Redox Biol, 2024 75:103292
- J Control Release, 2024 373:55-69
- J Nanobiotechnology, 2024 22(1):105
- Cancer Lett, 2024 586:216695
- Cancer Lett, 2024 588:216797
- Cell Death Dis, 2024 15(7):480
- Cell Death Dis, 2024 15(3):187
- Cell Rep, 2024 43(4):114041
- Cell Commun Signal, 2024 22(1):560
- Oncogene, 2024 10.1038/s41388-024-03143-9
- Aging Cell, 2024 24(1):e14361.
- EMBO Rep, 2024
- Blood Adv, 2024 8(20):5315-5329
- Breast Cancer Res, 2024 26(1):35
- Cell Death Discov, 2024 10(1):503
- Cancer Immunol Immunother, 2024 73(7):121
- Biochem Pharmacol, 2024 229:116495
- Int J Mol Sci, 2024 25(19)10863
- Int J Mol Sci, 2024 25(16)8590
- Int J Mol Sci, 2024 25(4)2288
- Int J Mol Sci, 2024 25(13)7438
- Int J Mol Sci, 2024 25(3)1427
- Oncotarget, 2024 15:328-344
- Aging (Albany NY), 2024 16(16):11904-11916
- Hepatol Commun, 2024 8(5)e0437
- Hepatol Commun, 2024 8(2)e0378
- Front Oncol, 2024 14:1357996
- Molecules, 2024 29(8)1737
- Sci Rep, 2024 14(1):6764
- BMC Chem, 2024 18(1):164
- Toxicology, 2024 509:153980
- BMC Cancer, 2024 24(1):1542
- DNA Repair (Amst), 2024 143:103770
- Ann Surg Oncol, 2024 10.1245/s10434-024-15355-0
- Biochem Biophys Res Commun, 2024 740:151015
- Oncol Lett, 2024 28(3):446
- Exp Hematol, 2024 S0301-472X(24)00516-2
- Sci Adv, 2024 10(11):eadk0785
- Cell Genom, 2024 4(2):100487
- Discov Oncol, 2024 15(1):709
- Cell Insight, 2024 3(5):100183
- Nat Commun, 2023 14(1):7576
- Nat Commun, 2023 14(1):4003
- Nat Commun, 2023 14(1):8406
- Mol Cell, 2023 83(5):803-818.e8
- Nucleic Acids Res, 2023 10.1093/nar/gkad973
- Acta Pharm Sin B, 2023 13(6):2680-2700
- J Exp Clin Cancer Res, 2023 42(1):14
- EMBO Mol Med, 2023 e16431.
- Clin Transl Med, 2023 13(12):e1509
- Cell Death Dis, 2023 14(1):64
- Elife, 2023 12e83867
- J Pathol, 2023 261(3):256-268
- Cell Death Discov, 2023 9(1):120
- Antioxidants (Basel), 2023 13(1)3
- iScience, 2023 26(7):107003
- Front Bioeng Biotechnol, 2023 11:1229490
- Int J Mol Sci, 2023 24(12)10400
- Int J Mol Sci, 2023 24(15)11988
- Int J Mol Sci, 2023 24(24)17589
- Int J Mol Sci, 2023 24(3)2498
- Cancers -Basel), 2023 15(14)3728
- Pathobiology, 2023 10.1159/000530430
- Front Oncol, 2023 13:1158857
- Front Oncol, 2023 13:1159484
- Sci Rep, 2023 13(1):5632
- Sci Rep, 2023 13(1):16606
- Metabolites, 2023 13(7)865
- BMC Cancer, 2023 23(1):677
- World J Surg Oncol, 2023 21(1):194
- BMC Pharmacol Toxicol, 2023 24(1):56
- FEBS Open Bio, 2023 13(6):1001-1014
- Exp Hematol, 2023 S0301-472X(23)00021-8
- bioRxiv, 2023 2023.05.19.540602
- bioRxiv, 2023 2023.10.28.564489
- Bioact Mater, 2022 16:204-217
- Nat Commun, 2022 13(1):6226
- Leukemia, 2022 10.1038/s41375-022-01776-x
- Cell Death Dis, 2022 13(7):643
- Cell Chem Biol, 2022 29(10):1517-1531.e7
- J Transl Med, 2022 20(1):276
- Cell Death Discov, 2022 8(1):438
- Drug Deliv, 2022 29(1):1698-1711
- Cancer Cell Int, 2022 22(1):326
- Mol Cancer Ther, 2022 21(11):1689-1700
- Front Pharmacol, 2022 13:1032975
- Int J Mol Sci, 2022 23(15)8338
- Int J Mol Sci, 2022 23(12)6425
- Int J Mol Sci, 2022 23(22)13751
- J Am Heart Assoc, 2022 11(13):e025266
- Cancers (Basel), 2022 14(19)4727
- Cancers (Basel), 2022 14(17)4196
- Cancers (Basel), 2022 14(21)5449
- Cancers (Basel), 2022 14(3)739
- Front Oncol, 2022 12:947492
- Sci Rep, 2022 12(1):9951
- Mol Carcinog, 2022 10.1002/mc.23470
- J Oncol, 2022 2022:2390078
- Biology (Basel), 2022 12(1)42
- J Cancer, 2022 13(15):3660-3673
- J Biochem Mol Toxicol, 2022 e23119
- J Bone Oncol, 2022 34:100429
- Hum Exp Toxicol, 2022 41:9603271221143693
- PeerJ, 2022 10:e14201
- J Breast Cancer, 2022 25(6):500-512
- Anticancer Drugs, 2022 33(7):622-631
- Eur J Histochem, 2022 66(4)3563
- J Exp Clin Cancer Res, 2021 40(1):322
- MedComm (2020), 2021 2(3):467-480
- Mol Cancer Ther, 2021 20(6):1210-1219
- Int J Mol Sci, 2021 22(21)11752
- Front Oncol, 2021 11:656687
- bioRxiv, 2021 10.1101/2021.08.19.456799
- University of Dundee, 2021 10.5281/zenodo.3727280
- Nanoscale Adv, 2020 2(10):4887-4894
- Proc Natl Acad Sci U S A, 2015 112(17):E2149-55
化学信息&溶解度
分子量 | 543.52 |
分子式 | C27H29NO11 |
CAS号 | 23214-92-8 |
Smiles | COC1=C2C(=O)C3=C(C(=C4CC(O)(CC(OC5CC(N)C(O)C(C)O5)C4=C3O)C(=O)CO)O)C(=O)C2=CC=C1 |
储存条件(自收到货起) | 3年 -20°C 粉状 |
建议分装储备液,避免反复冻融! |
|
体外溶解度 | 批次: |
DMSO : 100 mg/mL ( 183.98 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : 100 mg/mL Ethanol : Insoluble DMSO : 100 mg/mL ( 183.98 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : 100 mg/mL Ethanol : Insoluble DMSO : 100 mg/mL ( 183.98 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : 50 mg/mL Ethanol : Insoluble |
体内溶解度 | 批次: |
现配现用,请按从左到右的顺序依次添加,澄清后再加入下一溶剂 |
摩尔浓度计算器
质量(g)= 浓度(mol/L)* 体积(L)* 分子量(g/mol)
动物体内配方计算器(澄清溶液)
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,注:如该浓度超过该批次药物DMSO溶解度,请先联系Selleck);
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入 μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
体内配方配制方法:取 μL DMSO母液,加入 μL Corn oil,混匀澄清。
注意:
1. 首先保证母液是澄清的;
2.一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。